secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001193125-23-249556
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology receives $50M from BARDA for next-gen COVID-19 mAb and pandemic preparedness
--------------------------------------------------------------------------------

- BARDA awards $40M via Project NextGen for VIR-7229 Phase 1 trial, expected completion H2 2025.
- Additional $10M for discovery of mAbs against a second pandemic-potential pathogen.
- Vir also receives ~$11M to wind down PENINSULA trial of influenza A mAb VIR-2482.
- Existing BARDA Agreement allows up to $1B total investment; $55M already provided for VIR-2482.
- Funds support alternative mAb delivery technologies for COVID-19 and broader pandemic response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523249556/0001193125-23-249556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523249556/d554605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-249556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer